...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncoimmunology. >Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy
【24h】

Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy

机译：肿瘤浸润淋巴细胞，PD-L1表达与HPV / P16在头部和颈部癌症中的临床相关性，用生物或化疗治疗生物癌症治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To investigate the prognostic value of tumor infiltrating lymphocytes (TILs: CD8+ and FoxP3+), and PD-L1 expression in patients with head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy combined with cisplatin (CRT) or cetuximab (BRT). Immunohistochemistry for CD8, FoxP3 was performed on pretreatment tissue samples of 77 HNSCC patients. PD-L1 results were evaluable in 38 patients. Cox regression analysis was used to analyze the correlations of these biomarkers expression with clinicopathological characteristics and treatment outcomes. High CD8+ TILs level was identified in multivariate analysis (MVA) as an independent prognostic factor for improved progression-free survival with a non-significant trend for better overall survival (OS). High FoxP3+ TILs and PD-L1+ correlated with a favorable OS in the uni-variate analysis, respectively, but not in the MVA. In subgroup analysis, CD8+TILs appear to play a pivotal role, p16+/high CD8+TILs patients had superior 5-year OS compared with p16+/low CD8+TILs, p16-/ high CD8+TILs, and p16-/ low CD8+TILs patients. p16+/PD-L1+ patients had improved 3-year OS compared with p16+/PD-L1-, p16-/ PD-L1+, and p16-/ PD-L1- patients. In low CD8+ TILs tumors, 5-year loco-regional control of patients treated with CRT was improved vs. those with BRT (p = 0.01) while no significant difference in high CD8+ TILs was observed. CD8+ TILs correlated with an improved clinical outcome in HNSCC patients independent of Human papillomavirus status. The immunobiomarkers may provide information for selecting suitable patients for cisplatin or cetuximab treatment. Additionally, the impact of TILs and PD-L1 of deciphering among the p16+ population a very favorable outcome population could be of interest for patients tailored approaches.
机译：探讨肿瘤浸润淋巴细胞（TILS：CD8 +和Foxp3 +）的预后值，以及用放疗与顺铂（CRT）或西列特蛋白（BRT）相结合的头颈鳞状细胞癌（HNSCC）患者的PD-L1表达。 CD8的免疫组织化学，对77例HNSCC患者的预处理组织样品进行FOXP3。 PD-L1结果是在38例患者中进行评价。 Cox回归分析用于分析这些生物标志物表达与临床病理特征和治疗结果的相关性。在多变量分析（MVA）中鉴定出高CD8 + TILS水平，作为改善无进展生存期的独立预后因素，以具有更好的整体存活（OS）的非显着趋势。高Foxp3 + Tils和PD-L1 +分别与UNI - 变化分析中的有利操作系统相关，但不在MVA中。在亚组分析中，CD8 + TILs似乎发挥枢轴作用，P16 + /高CD8 +直到患者的患者患有卓越的5年OS，与P16 + /低CD8 + TIL，P16- /高CD8 + TIL和P16- /低CD8相比+ Tils患者。 P16 + / PD-L1 +患者与P16 + / PD-L1，P16- / PD-L1 +和P16- / PD-L1-患者进行了改善的3年OS。在低CD8 + TILS肿瘤中，5岁的患者对CRT治疗的患者进行改善，与BRT（P = 0.01）进行改善，同时观察到高CD8 + TIL的显着差异。 CD8 + TILs与HNSCC患者的改善临床结果相关，与人乳头瘤病毒状态无关。免疫标志物可以提供用于选择合适的顺铂或西列特昔单抗治疗患者的信息。此外，TILS和PD-L1的影响在P16 +群体中解密的影响非常有利的结果群体对于量身定制的方法可能具有感兴趣的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号